---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005100"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:58:05.538757+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity

## Summary
- Stockholders' equity of -$5.545M as of Dec 31, 2022, below Nasdaq's $2.5M minimum requirement.
- Company has until May 11, 2023 to submit a compliance plan to regain listing compliance.
- No immediate effect on Nasdaq listing; company intends to submit a plan and consider options.
- Alternative compliance standards (market value or net income) also not met.

## SEC filing metadata
- accession: 0001558370-23-005100
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/0001558370-23-005100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/agrx-20230327x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005100
- JSON: https://secwatch.observer/filing/0001558370-23-005100.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005100.txt

## Key facts
- Listing & Compliance Notices
  AGILE THERAPEUTICS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form 8-K, the Company does not
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/0001558370-23-005100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.